See What HealthDay Can Do For You
Contact Us

Company Seeks FDA Emergency Approval for COVID-19 Antibody Therapy

Request based on partial clinical trial findings suggesting the drug reduces symptoms in mild or moderate COVID-19

fda logo

WEDNESDAY, Oct. 7, 2020 (HealthDay News) -- Eli Lilly and Co. is seeking U.S. approval for emergency use of an experimental antibody therapy for COVID-19.

The request to the U.S. Food and Drug Administration is based on partial clinical trial findings suggesting the drug reduced symptoms, the amount of virus, hospitalizations, and emergency department visits for patients with mild or moderate COVID-19, the Associated Press reported.

The results were released Wednesday in a news release, and they have not been published or reviewed by independent researchers.

The FDA granted emergency approval for the antiviral drug remdesivir, but it is not clear if there is enough evidence for Lilly's antibody therapy to be approved, the AP reported.

AP News Article

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.